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1. Introduction
  Gout and hyperuricemia are the common metabolic 
disorders in human, associated with an elevated uric 
acid level in the blood[1], leading to the deposition of 
urate crystals in the joints and kidneys, leading to gouty 
arthritis and uric acid nephrolithiasis. Xanthine oxidase 
(XO) and xanthine dehydrogenase (XDH) are the two 
interconvertible forms of same gene product known as 
xanthine oxidoreductase (XOR). It catalyses the oxidation 
of hypoxanthine to xanthine and then to uric acid, the 
final reactions in the metabolism of purine bases[2,3]. The 
treatment for gout is either increasing the excretion of uric 
acid or reducing the uric acid production. Xanthine oxidase 
inhibitors (XOIs) are much useful, since they possess lesser 
side effects compared to uricosuric and anti-inflammatory 
agents. Allopurinol is the only clinically used XOI, which 
also suffers from many side effects such as hypersensitivity 
syndrome, Stevens Johnson syndrome and renal toxicity[4]. 
Thus, there is a need to develop compounds with XOI 
activity which are devoid of the undesirable side effects 
of allopurinol. A potential source of such compounds can 
be obtained from medicinal plants[5,6]. Flavonoids and 
polyphenolic crude extracts have been reported to possess 
xanthine oxidase inhibitory activity[1,7,8]. Crateva adansonii 
(C. adansonii) belonging to the family Capparaceae and 
phylum Magnoliophyta is small  tree of forest and savanna 
woodland,often on river-banks, widely distributed in 
Nigeria,and Across Africa[9,10]. The leaves are applied 
externally to relieve pain in joints; the fresh juice of leaves 
is used for the relief of ear ache, eye infection and anodyne 
in toothache. Powder of bark is used in rheumatism, itch, 
epilepsy, and asthma[11]. Many medicinal plants have been 
used for the prevention and treatment of gout and related 
inflammatory disorders,but they lack sufficient scientific 
evidence. Hence, the objective of the present study is to 
determine the in vitro xanthine oxidase inhibitory activity 
of the fractions of the leaves C. adansonii and its enzyme 
inhibition mechanism.
Objective: To study the inhibitory effect of various extracts from Crateva adansonii (C. 
adansonii) used traditionally against several inflammatory diseases such as rheumatism, arthritis, 
and gout, was investigated on purified bovine milk xanthine oxidase (XO) activity. Methods: 
Xanthine oxidase inhibitory activity was assayed spectrophotometrically and the degree of 
enzyme inhibition was determined by measuring the increase in absorbance at 295 nm associated 
with uric acid formation. Enzyme kinetics was carried out using Lineweaver-Burk plots using 
xanthine as the substrate. Results: Among the fractions tested, the chloroform fraction exhibited 
highest potency (IC50 20.2依1.6 毺g/mL) followed by the petroleum ether (IC50 30.1依2.2 毺g/mL), 
ethyl acetate (IC50 43.9依1.4 毺g/mL) and residual (IC50 98.0依3.3 毺g/mL) fractions. The IC50 value 
of allopurinol used, as the standard was 5.7依0.3 毺g/mL. Conclusions: Enzyme inhibition 
mechanism indicated that the mode of inhibition was of a mixed type. Our findings suggest that 
the therapeutic use of these plants may be due to the observed Xanthine oxidase inhibition, 
thereby supporting their use in traditional folk medicine against inflammatory-related diseases, 
in particular, gout.
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2. Materials and methods
2.1. Plant material
  The plant material consists of dried powdered leaves 
of C. adansonii belonging to the family Capparaceae 
and phylum Magnoliophyta. The leaves were collected 
in and around Minna. Niger State of Nigeria and 
was authenticated by the staff of Biological Science 
Department of Federal University of Technology, Minna.
2.2. Preparation of the extract and fractionation
  The air-dried powdered leaves of C. adansonii (500 
g) were extracted with methanol-water (7:3) mixture 
using a mechanical shaker for 4 h. The resultant 
extract was concentrated under reduced pressure to 
yield a residue. The hydromethanolic extract was then 
extracted successively with equal volumes of petroleum-
ether, chloroform and ethyl acetate. Each fraction was 
then concentrated under reduced pressure to obtain 
petroleum-ether fraction (PEF), chloroform fraction (CF), 
ethyl acetate fraction (EAF) and residual fraction (RF).
2.3. Chemicals
  XO (source: Bovine Milk) XO was purified from bovine 
milk using the method of Atmani et al[12] and XO was kept 
frozen and thawed just before use. The buffer used in our 
study was 0.1 M monopotassium phosphate-disodium 
phosphate (KH2PO4/Na2HPO4), and xanthines were 
obtained from Department of Biochemistry Laboratory 
Federal University of Technology, Minna. Allopurinol was 
obtained from Zagbayi pharmaceutical Minna. All other 
drugs and chemicals used in the study were obtained 
commercially and were of analytical grade.
2.4. Phytochemical screening
  Preliminary phytochemical screening of the plant extract 
was performed for the presence of alkaloids, phenolics, 
tannins, flavonoids, saponins, carotenoids, carbohydrates 
and glycosides[13].
2.5. In vitro xanthine oxidase inhibitory activity
  All the fractions of C. adansonii were assayed for their in 
vitro xanthine oxidase inhibitory activity.The XOI activity 
was assayed spectrophotometrically using xanthine as 
the substrate[14]. The assay mixture consisted of 1 mL of 
the fraction (5-100 毺g/mL), 2.9 mL of phosphate buffer 
(pH 7.5) and 0.1 mL of xanthine oxidase enzyme solution 
(0.1 units/mL in phosphate buffer, pH 7.5), which was 
prepared immediately before use. 
  After preincubation at 25 曟 for 15 min, the reaction was 
initiated by the addition of 2 mL of the substrate solution 
(150 mM xanthine in the same buffer). The assay mixture 
was incubated at 25 曟 for 30 min. The reaction was then 
stopped by the addition of 1 mL of 1 N hydrochloric acid 
and the absorbance was measured at 290 nm using a 
UV spectrophotometer[15,16]. Different concentrations of 
the fractions (5-100 毺g/mL) were dissolved in dimethyl 
sulfoxide (DMSO) and the final concentration of DMSO was 
5%, which did not affect the enzyme assay. 
  Proper controls with DMSO were carried out. Allopurinol 
(5-100 毺g/mL), a known inhibitor of XO, was used as the 
positive control. One unit of XO is defined as the amount 
of enzyme required to produce 1mmol of uric acid/min 
at 25 曟. XOI activity was expressed as the percentage 
inhibition of XO in the above assay system calculated as
  Inhibition (%) = (1-[B/A])×100, where A represents the 
activity of the enzyme without plant extract and B is the 
activity of XO in the presence of plant extract. 
  The enzymatic inhibitory mode of action of different 
extracts from both plants that exhibited the highest 
inhibition of XO activity was determined by the 
Lineweaver-Burk plot using varying concentrations of 
xanthine.
2.6. Enzyme inhibition mechanism
  To determine the mode of inhibition by the most active 
chloroform fraction, Lineweaver-Burk plot analysis was 
performed. The assay was carried out in the absence 
and presence of the chloroform fraction with varying 
concentrations of xanthine as the substrate, using the 
XO assay methodology. The mode of inhibition was 
compared with that of the positive control allopurinol. 
The Lineweaver-Burk transformed valueswere plotted to 
determine the mode of inhibition[17,18].
3. Results
  Preliminary phytochemical screening of the plant extract 
revealed the presence of phenolics, alkaloids, flavonoids 
and saponins (Table 1). All the fractions of C. adansonii 
elicited a dose dependent inhibition of xanthine oxidase 
enzyme activity. Inhibition of xanthine oxidase resulted in 
a decreased production of uric acid, which was measured 
spectrophotometrically. 
  At a concentration of 100 毺g/mL, highest activity was 
observed in the chloroform fraction followed by the 
petroleum-ether, ethyl acetate and residual fractions. 
The concentration of the fractions at which 50% of the 
xanthine oxidase inhibitory activity (IC50) was calculated. 
  These results were compared with the standard drug 
allopurinol, which showed (92.25依0.05)% inhibition at 
100 毺g/mL concentration with IC50 value (5.7依0.3) 毺g/mL 
(Table 2).
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  The inhibition mechanism of the chloroform fraction 
of C. adansonii, which is a potent inhibitor of xanthine 
oxidase, was studied by kinetic analysis using double-
reciprocal plotting. Lineweaver-Burk plots of reactions in 
the presence and absence of the chloroform fraction in a 
xanthine oxidase reaction mixture is shown in Figure 1.
  The mode of inhibition was investigated and compared 
with the standard drug, allopurinol. The data indicates that 
the mode of xanthine oxidase inhibition for the chloroform 
fraction is of mixed type (between uncompetitive and non-
competitive type of inhibition). 
  Therefore, the fraction inhibited XO by binding either 
with the free enzyme or the enzyme-substrate complex.
 
Figure 1. Lineweaver-Burk plot of inhibition of xanthine oxidase 
by chloroform fraction of C. adansonii (▄) and allopurinol (▲). 
The symbol (燐) represents negative control. 
4. Discussion
  Recent findings show that the occurrence of gout is 
increasing worldwide, possibly due to the changes in 
dietary habits like intake of food rich in nucleic acids, 
such as meat and seafoods. Hypouricemic agents are 
commonly employed for the treatment of chronic gouty 
arthritis, which includes xanthine oxidase inhibitors and 
uricosuric agents[19]. In general, allopurinol is the drug 
of choice; however it has serious side effects. Thus, new 
alternatives with increased therapeutic activity and lesser 
side effects are desired. We thus began our program to 
look for xanthine oxidase inhibitors of phytochemical 
origin from the various fractions of the hydromethanolic 
extract of the leaves of C. adansonii. The leaves of 
C. adansonii are being frequently used in Nigeria traditional 
medicinal system for the treatment joint pain and related 
inflammatory disorders. 
  All the fractions of C. adansonii inhibited xanthine 
oxidase in a concentration-dependent manner. The in 
vitro inhibition of xanthine oxidase by the chloroform 
fraction is moderate when compared to allopurinol. 
However, at higher doses of the fraction, xanthine oxidase 
would be significantly inhibited. Flavonoids are a group 
of polyphenolic compounds, which have been reported to 
possess xanthine oxidase inhibitory activity[20]. 
  Hence, the presence of phenolic and flavonoid content 
in the extract would have contributed towards xanthine 
oxidase inhibition. 
  In conclusion, the study suggests that C. adansonii 
Table 1
Phytochemical screening of C. adansonii.
Ingredient Petroleum-ether Chloroform Ethyl acetate
Alkaloids + + +
Phenolics + + +
Tannins - - -
Flavonoids + + +
Saponins + + +
Carotenoids - - -
Carbohydrates - - -
Glycosides - - -
Balsams - - -
Key: (+) present, (-) - absent.
Table 2
Percentage yield and xanthine oxidase inhibitory activity of the fractions of C. adansonii.
Fraction % Yield fraction (w/w)
Percentage xanthine oxidase inhibition
IC50 (毺g/mL)5 毺g/mL 10 毺g/mL 25 毺g/mL 50 毺g/mL 100 毺g/mL 
Petroleum-ether 1.8 28.35 依 0.90 39.53 依 1.20 48.32 依 0.90 66.73 依 1.57 78.59 依 1.60 30.10 依 2.20
Chloroform 1.7 19.55 依 1.30 36.00 依 0.80 55.00 依 1.00 76.70 依 1.10 84.75 依 0.50 20.20 依 1.60
Ethyl acetate 0.9 11.85 依 0.30 23.75 依 0.70 39.50 依 1.00 56.35 依 1.20 64.55 依 1.50 43.90 依 1.40
Residual 5.1   5.90 依 1.10 28.80 依 1.20 35.70 依 0.50 41.50 依 1.20 50.05 依 1.80 98.00 依 3.30
Allopurinol 44.91 依 1.80 66.91 依 0.80 75.00 依 1.40 85.46 依 0.80 92.25 依 0.50   5.70 依 0.30
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leaves possess xanthine oxidase inhibitory activity that 
might be helpful in preventing or slowing the progress 
of gout. Further in vivo experiments and the isolation 
and identification of active compounds present in the 
leaves should be carried out to identify a potential 
chemical entity for clinical use in the prevention and 
treatment of gout and related inflammatory disorders.
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